1. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PKS, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32–45
2. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–715
3. Mullard A (2011) 2010 FDA drug approvals. Nat Rev Drug Discov 10:82–85
4. Kola I (2008) The state of innovation in drug development. Clin Pharmacol Ther 83:227–230
5. FDA (2004) Challenge and opportunity on the critical path to new medical products. US Department of Health and Human Services, F (ed), FDA, Rockville.
http://wcms.fda.gov/FDAgov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm